N/A
N=101
Quality of Life After Interventional Thyroid Treatment
Thyroid; Deficiency · Quality of Life
Bottom Line
View on ClinicalTrials.gov: NCT03880578 ↗Enrolled (actual)
101
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: ThyPRO Scale Scores (0-100, Higher Scores Indicating Worse Quality of Life) — 18.3; 19.9 score — p=<0.001
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Levothyroxine Sodium (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Klinikum Lüdenscheid
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ThyPRO Scale Scores (0-100, Higher Scores Indicating Worse Quality of Life) |
18.3; 19.9 | <0.001 sig |
| SECONDARY Rate of Global Deiodinase Activity (SPINA-GD, See Reference Calculated Parameters) |
32.9; 32.2 | 0.06 |
Summary
In this study, patients are prospectively followed after radioiodine treatment to assess the relationship between thyroid status and their quality of life after thyroid ablative treatment.
A third treatment arm after surgery has been stopped, as deemed currently not feasible to achieve its target.
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of a thyroid disease requiring radioiodine treatment
- Clinical diagnosis of a thyroid disease requiring follow-up but no ablative treatment (controls)
- Clinical diagnosis of a thyroid disease requiring surgery stopped recruiting
Exclusion Criteria
- paediatric patients
- interfering comorbidity
- non-thyroidal illness
- pregnancy
- psychiatric disease
- severe psychological disorder
- lack of consent
Data sourced from ClinicalTrials.gov (NCT03880578). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.